Lilly chief exec affirms company is not for sale

Share this article:

Eli Lilly's chief executive said his company is not for sale, boasts a
healthy pipeline and plans on producing top growth for years to
come, during television appearance yesterday.
Sidney Taurel said on CNBC Thursday that, historically, mergers
have not created shareholder value "in a sustainable fashion."
The chief executive also discussed a Dec. 2 lawsuit Lilly filed in Indiana district court seeking to stop Barr Pharmaceuticals from marketing a generic version of Zyprexa, Lilly's largest drug with sales of $233 million in the 12 months ending in September. "We really don't know when the judgment will come," Taurel said.
Speaking on pharma companies' relationships with consumers following the withdrawal of Vioxx, Taurel said, "This is the most challenging period I've seen in my career."                       

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...